Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel
- 20 April 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 24 (9), 1691-1701
- https://doi.org/10.1007/s11095-007-9298-0
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer®) in recurrent ovarian cancer: A Gynecologic Oncology Group studyGynecologic Oncology, 2006
- Nanoparticle Albumin–Bound Paclitaxel for Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast CancerJournal of Clinical Oncology, 2005
- Absorption characteristics of model compounds from the small intestinal serosal surface and a comparison with other organ surfacesJournal of Pharmacy and Pharmacology, 2005
- Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer TherapyClinical Cancer Research, 2004
- Intraperitoneal cisplatin‐based chemotherapy vs. intravenous cisplatin‐based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancerInternational Journal of Gynecology & Obstetrics, 2001
- Absorption of Insulin in the Peritoneal Cavity in a Diabetic Animal ModelArtificial Organs, 1993
- Pharmacologic Study of Etoposide and Cisplatin by the Intraperitoneal RouteThe Journal of Clinical Pharmacology, 1991
- Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancerGynecologic Oncology, 1990
- Structure of the intestinal peritoneum in manJournal of Anatomy, 1941